Evaluating the effectiveness of cancer drug sensitization in vitro and in vivo.
Due to the high level of heterogeneity and mutations inherent in human cancers, single agent therapies, or combination regimens which target the same pathway, are likely to fail. Emphasis must be placed upon the inhibition of pathways that are responsible for intrinsic and/or adaptive resistance to therapy. An active field of investigation is the development and testing of DNA repair inhibitors that promote the action of, and prevent resistance to, commonly used chemotherapy and radiotherapy. We used a novel protocol to evaluate the effectiveness of BRCA2 inhibition as a means to sensitize tumor cells to the DNA damaging drug cisplatin. Tumor cell metabolism (acidification and respiration) was monitored in real-time for a period of 72 hr to delineate treatment effectiveness on a minute by minute basis. In combination, we performed an assessment of metastatic frequency using a chicken embryo chorioallantoic membrane (CAM) model of extravasation and invasion. This protocol addresses some of the weaknesses of commonly used in vitro and in vivo methods to evaluate novel cancer therapy regimens. It can be used in addition to common methods such as cell proliferation assays, cell death assays, and in vivo murine xenograft studies, to more closely discriminate amongst candidate targets and agents, and select only the most promising candidates for further development.
Microbiology and Immunology, Western University.
Mateusz
M
Rytelewski
Biochemistry, Western University.
Adrian
A
Buensuceso
Surgery, Western University.
Hon S
HS
Leong
Biochemistry, Western University.
Bonnie J
BJ
Deroo
Oncology, Western University.
Ann F
AF
Chambers
Microbiology and Immunology, Western University; jkoropatnick@gmail.com.
James
J
Koropatnick
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D024682:BRCA2 Protein / Q000235:genetics; D002642:Chick Embryo; D049033:Chorioallantoic Membrane / Q000187:drug effects*; D002945:Cisplatin / Q000008:administration & dosage / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D004357:Drug Synergism; D006801:Humans; D051379:Mice; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000235:genetics / Q000494:pharmacology*
D000970:Antineoplastic Agents; D024682:BRCA2 Protein; C551750:BRCA2 protein, human; D016376:Oligonucleotides, Antisense; D002945:Cisplatin